PhaseBio Pharmaceuticals has closed a $40 million Series C financing round led by AstraZeneca.
Investment by AstraZeneca and existing investors New Enterprise Associates, Hatteras Venture Partners, Johnson & Johnson Innovation – JJDC and Fletcher Spaght Ventures will enable progression of PhaseBio’s once-weekly insulin (PE0139) into Phase 2a testing for type 2 diabetes and once-weekly Vasoactive Intestinal Peptide (PB1046) into separate Phase 2a trials for heart failure and for cardiomyopathy in Duchenne and Becker muscular dystrophy.
|Searching for more deal information? Current Partnering offers the following options:|
- CP Reports | Browse titles | Over 200 report titles that focus upon different deal types from licensing, co-promotion to distribution, biomarkers to drug delivery, oncology to psychiatry, all of which provide you with an insight into the latest life science deal making trends
- Current Agreements | Login | Find out more | Updated daily by our industry analysts, our fully searchable life sciences intelligence database allows you to find deals and alliances dating as far back as 2000 saving you valuable time on your deal making research activities
- CP Knowledge Centre | Login | Find out more | Provides you with an all-in-one intelligence package that allows you to simultaneously access our CP reports, CP Insight and Current Agreements deal and alliances database, at the same time
RelatedFor further deal information visit Current Agreements (subscription required)
Scorecard: Top partnering deals by value in 2015
View: Top pharmaceutical companies
View: Top biotech companies
Reports: Browse our extensive deal making report portfolio